Anthony Eugene Oro, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Oro’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G79854 · Current
Licensed to practise in California · since 1994 · expires 2027-11-30 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$14,752
Medicare paid this office $14,752 for 114 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 80 | $9,432 | $81 |
| Short return visit (20+ min) | 36 | $2,327 | $60 |
Procedures Medicare counted
| Removal of skin lesions | 25 | More than 67% of doctors who do this |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
114 Original Medicare patients in 2024. Average age 73 · Women 87% · Health risk score 0.83. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 47% · Coronary heart disease 17% · Cancer 15% · Diabetes 14% · Chronic kidney disease 13% · Depression 12%.
The office billed $53,103, Medicare allowed $21,244 and paid $14,752; for 245 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 114 | 245 | 73 | 0.83 | $53,103 | $14,752 |
| 2023 | 136 | 311 | 72 | 0.83 | $53,157 | $17,114 |
| 2022 | 126 | 375 | 72 | 0.81 | $65,060 | $17,084 |
| 2021 | 106 | 424 | 73 | 0.85 | $66,107 | $15,230 |
| 2020 | 95 | 266 | 72 | 0.89 | $48,085 | $7,411 |
| 2019 | 113 | 333 | 73 | 1.05 | $34,665 | $10,013 |
| 2018 | 106 | 399 | 74 | 1.09 | $33,885 | $9,549 |
| 2017 | 89 | 367 | 73 | 1.23 | $31,159 | $9,282 |
| 2016 | 115 | 453 | 73 | 1.05 | $44,623 | $12,539 |
| 2015 | 113 | 406 | 72 | 1.16 | $43,981 | $12,068 |
| 2014 | 100 | 411 | 74 | 1.00 | $43,333 | $11,015 |
| 2013 | 102 | 422 | 73 | 0.98 | $41,662 | $10,725 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 78 | $9,424 | $83 |
| Short return visit (20+ min) | 49 | $2,769 | $50 |
| New patient visit (45+ min) | 23 | $2,536 | $110 |
| Destruction of precancer skin growth, 1 growth | 18 | $818 | $39 |
| Destruction of precancer skin growth, 2-14 growths | 13 | $106 | $2 |
2022: 6 services
| Return visit (30+ min) | 68 | $7,812 | $77 |
| Short return visit (20+ min) | 57 | $3,179 | $50 |
| New patient visit (45+ min) | 21 | $2,184 | $104 |
| Destruction of precancer skin growth, 1 growth | 26 | $1,365 | $44 |
| Injection into skin growth, 1-7 growths | 16 | $295 | $16 |
| Destruction of precancer skin growth, 2-14 growths | 22 | $155 | $2 |
2021: 5 services
| Return visit (30+ min) | 42 | $6,043 | $85 |
| Short return visit (20+ min) | 67 | $4,553 | $49 |
| Destruction of precancer skin growth, 1 growth | 31 | $1,610 | $41 |
| Biopsy of related skin growth, first growth | 18 | $360 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 26 | $255 | $2 |
2020: 4 services
| Short return visit (20+ min) | 66 | $3,387 | $39 |
| Return visit (30+ min) | 26 | $1,427 | $48 |
| Destruction of precancer skin growth, 1 growth | 18 | $754 | $38 |
| Destruction of precancer skin growth, 2-14 growths | 17 | $116 | $1 |
2019: 6 services
| Short return visit (20+ min) | 74 | $3,452 | $39 |
| Return visit (30+ min) | 36 | $2,647 | $65 |
| Destruction of precancer skin growth, 1 growth | 28 | $1,109 | $36 |
| New patient visit (30+ min) | 11 | $747 | $68 |
| Biopsy of related skin growth, first growth | 11 | $349 | $25 |
| Destruction of precancer skin growth, 2-14 growths | 22 | $176 | $2 |
2018: 7 services
| Short return visit (20+ min) | 83 | $4,145 | $42 |
| Destruction of precancer skin growth, 1 growth | 45 | $1,882 | $37 |
| Return visit (30+ min) | 12 | $699 | $58 |
| New patient visit (30+ min) | 13 | $683 | $53 |
| Destruction of skin growth, 1-14 growths | 12 | $632 | $53 |
| Biopsy of single growth of skin and/or tissue | 13 | $354 | $27 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $316 | $2 |
2017: 7 services
| Short return visit (20+ min) | 65 | $3,480 | $42 |
| Destruction of precancer skin growth, 1 growth | 33 | $1,687 | $41 |
| Return visit (30+ min) | 13 | $975 | $65 |
| New patient visit (30+ min) | 15 | $814 | $54 |
| Destruction of skin growth, 1-14 growths | 12 | $788 | $61 |
| Biopsy of single growth of skin and/or tissue | 16 | $528 | $31 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $304 | $2 |
2016: 7 services
| Short return visit (20+ min) | 85 | $4,597 | $41 |
| Destruction of precancer skin growth, 1 growth | 41 | $2,232 | $41 |
| Return visit (30+ min) | 15 | $1,205 | $60 |
| Destruction of skin growth, 1-14 growths | 14 | $981 | $61 |
| New patient visit (30+ min) | 19 | $957 | $50 |
| Biopsy of single growth of skin and/or tissue | 15 | $554 | $33 |
| Destruction of precancer skin growth, 2-14 growths | 30 | $371 | $2 |
2015: 6 services
| Short return visit (20+ min) | 79 | $4,033 | $41 |
| Destruction of precancer skin growth, 1 growth | 42 | $2,309 | $47 |
| New patient visit (30+ min) | 27 | $1,513 | $56 |
| Return visit (30+ min) | 12 | $1,405 | $67 |
| Biopsy of single growth of skin and/or tissue | 16 | $553 | $33 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $330 | $2 |
2014: 5 services
| Short return visit (20+ min) | 71 | $3,768 | $39 |
| Destruction of precancer skin growth, 1 growth | 38 | $2,008 | $41 |
| New patient visit (30+ min) | 21 | $1,270 | $60 |
| Biopsy of single growth of skin and/or tissue | 15 | $527 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 34 | $340 | $2 |
2013: 6 services
| Short return visit (20+ min) | 69 | $3,254 | $37 |
| Destruction of precancer skin growth, 1 growth | 39 | $2,438 | $47 |
| New patient visit (30+ min) | 29 | $1,786 | $62 |
| Biopsy of single growth of skin and/or tissue | 23 | $770 | $30 |
| Destruction of precancer skin growth, 2-14 growths | 35 | $669 | $4 |
| Short return visit | 11 | $194 | $18 |
Drugs they prescribed that Part D paid
$66,146
Pharmacies billed $66,146 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 740) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
727 generic and 13 brand-name prescriptions · $66,146 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Litfulo | 11 | $43,440 | $3,949 |
| Minoxidil | 320 | $4,401 | $14 |
| Finasteride | 159 | $1,939 | $12 |
| Dutasteride | 68 | $1,886 | $28 |
| Clobetasol Propionate | 29 | $1,302 | $45 |
See all 9 drugs
| Litfulo | 11 | $43,440 | $3,949 |
| Minoxidil | 320 | $4,401 | $14 |
| Finasteride | 159 | $1,939 | $12 |
| Dutasteride | 68 | $1,886 | $28 |
| Clobetasol Propionate | 29 | $1,302 | $45 |
| Hydroxychloroquine Sulfate | 31 | $975 | $31 |
| Fluocinonide | 21 | $817 | $39 |
| Ketoconazole | 38 | $467 | $12 |
| Doxycycline Hyclate | 15 | $407 | $27 |
Year by year
| 2024 | 740 | 102 | 0% (0) | 2% | $66,146 |
| 2023 | 578 | 100 | 0% (0) | None | $54,884 |
| 2022 | 291 | 65 | 0% (0) | 0% | $7,731 |
| 2021 | 190 | 54 | 0% (0) | 0% | $8,734 |
| 2020 | 156 | 50 | 0% (0) | None | $7,643 |
| 2019 | 216 | 58 | 0% (0) | 8% | $7,904 |
| 2018 | 243 | 63 | 0% (0) | 8% | $12,806 |
| 2017 | 229 | 59 | 0% (0) | 8% | $10,853 |
| 2016 | 217 | 60 | 0% (0) | 19% | $17,824 |
| 2015 | 254 | 67 | 0% (0) | 12% | $35,794 |
| 2014 | 182 | 53 | 0% (0) | 20% | $72,174 |
| 2013 | 204 | 54 | 0% (0) | 14% | $38,434 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Minoxidil | 237 | $3,326 | $14 |
| Dutasteride | 37 | $2,439 | $66 |
| Finasteride | 145 | $1,960 | $14 |
| Fluocinonide | 26 | $1,691 | $65 |
| Clobetasol Propionate | 23 | $1,170 | $51 |
| Doxycycline Hyclate | 17 | $897 | $53 |
| Hydroxychloroquine Sulfate | 27 | $748 | $28 |
| Ketoconazole | 30 | $376 | $13 |
2022: 6 drugs
| Dutasteride | 25 | $2,448 | $98 |
| Minoxidil | 107 | $1,287 | $12 |
| Clobetasol Propionate | 13 | $1,126 | $87 |
| Finasteride | 60 | $528 | $9 |
| Ketoconazole | 23 | $519 | $23 |
| Gabapentin | 16 | $228 | $14 |
2021: 6 drugs
| Dutasteride | 26 | $2,075 | $80 |
| Finasteride | 38 | $429 | $11 |
| Ketoconazole | 16 | $427 | $27 |
| Minoxidil | 36 | $427 | $12 |
| Triamcinolone Acetonide | 12 | $228 | $19 |
| Gabapentin | 17 | $101 | $6 |
2020: 5 drugs
| Hydroxychloroquine Sulfate | 14 | $1,118 | $80 |
| Dutasteride | 15 | $773 | $52 |
| Finasteride | 46 | $406 | $9 |
| Ketoconazole | 22 | $287 | $13 |
| Gabapentin | 12 | $41 | $3 |
2019: 7 drugs
| Hydroxychloroquine Sulfate | 14 | $1,395 | $100 |
| Dutasteride | 13 | $810 | $62 |
| Clobetasol Propionate | 13 | $799 | $61 |
| Finasteride | 60 | $595 | $10 |
| Triamcinolone Acetonide | 12 | $300 | $25 |
| Ketoconazole | 20 | $279 | $14 |
| Gabapentin | 17 | $88 | $5 |
2018: 8 drugs
| Hydroxychloroquine Sulfate | 24 | $2,553 | $106 |
| Desonide | 13 | $841 | $65 |
| Fluocinonide | 16 | $818 | $51 |
| Finasteride | 62 | $683 | $11 |
| Ketoconazole | 20 | $331 | $17 |
| Triamcinolone Acetonide | 21 | $290 | $14 |
| Gabapentin | 20 | $81 | $4 |
| Hydrocortisone | 11 | $65 | $6 |
2017: 5 drugs
| Clobetasol Propionate | 21 | $2,984 | $142 |
| Ketoconazole | 46 | $672 | $15 |
| Finasteride | 46 | $552 | $12 |
| Triamcinolone Acetonide | 21 | $282 | $13 |
| Hydrocortisone | 14 | $92 | $7 |
2016: 6 drugs
| Clobetasol Propionate | 26 | $5,111 | $197 |
| Fluocinonide | 14 | $808 | $58 |
| Triamcinolone Acetonide | 27 | $402 | $15 |
| Ammonium Lactate | 12 | $294 | $25 |
| Ketoconazole | 21 | $280 | $13 |
| Finasteride | 28 | $254 | $9 |
2015: 5 drugs
| Clobetasol Propionate | 46 | $9,322 | $203 |
| Econazole Nitrate | 24 | $3,380 | $141 |
| Triamcinolone Acetonide | 32 | $533 | $17 |
| Finasteride | 26 | $208 | $8 |
| Ketoconazole | 15 | $194 | $13 |
2014: 4 drugs
| Clobetasol Propionate | 29 | $6,037 | $208 |
| Desonide | 16 | $3,926 | $245 |
| Triamcinolone Acetonide | 11 | $216 | $20 |
| Finasteride | 21 | $173 | $8 |
2013: 9 drugs
| Simponi | 12 | $29,409 | $2,451 |
| Clobetasol Propionate | 40 | $1,291 | $32 |
| Desonide | 12 | $1,270 | $106 |
| Ketoconazole | 20 | $320 | $16 |
| Triamcinolone Acetonide | 15 | $259 | $17 |
| Ammonium Lactate | 11 | $220 | $20 |
| Acyclovir | 12 | $199 | $17 |
| Hydrocortisone | 15 | $197 | $13 |
| Finasteride | 11 | $104 | $9 |
Money from drug and device companies
$26 in 2024
| 2024 | 1 | 1 | None | $26 |
| 2023 | 1 | 2 | None | $31 |
| 2022 | 1 | 1 | None | $29 |
| 2020 | 1 | 1 | $3,100 | $3,100 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | None | $26 | 1 payment
|
See the published payment
| Abbvie | Meals · 2024-05-16 | None | $26 |
See earlier years (2023, 2022, 2020)
2023: $31
| Pfizer | Cibinqo | $31 | 2 payments
|
2022: $29
| Abbvie | None | $29 | 1 payment
|
2020: $3,100
| Regeneron Healthcare Solutions | Libtayo | $3,100 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| LEO Pharma AS · As Stnfd Gemsd · 2021 | Their institution | $270,000 |
| ABBVIE INC. · Biobanking Study for Patients With Aga · 2023 | Their institution | $100,000 |
| ABBVIE INC. · Research Study Which Will Bank Biopsy Samples From Patients With Androgenic Alopecia and Perform Genetic Sequencing and Analysis · 2024 | Their institution | $100,000 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1902963853
- Licence
- CA G79854California G79854: Current · expires 2027-11-30
- Trained
- University of California, San Diego School of Medicine, 1993
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-02
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 900 Blake Wilbur Dr, Palo Alto, CA, 94304 · 440 Broadway St Fl B4, Redwood City, CA, 94063